- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05844462
Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (ERASE PH-COPD)
April 3, 2024 updated by: Assistance Publique - Hôpitaux de Paris
Efficacy of Phosphodiesterase Type 5 Inhibitors in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups.
Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Pulmonary hypertension (PH) is a frequent complication of chronic parenchymal lung diseases particularly in chronic obstructive pulmonary disease (COPD) and represents one of the major cause of all causes of PH.
When present, PH contributes to more severe symptoms; exercise intolerance and can lead to right heart failure, which portends a worse prognosis and an increased mortality.
Mechanisms of severe PH in chronic respiratory diseases are complex and include rarefaction of vascular bed, endothelial dysfunction and exaggerated pulmonary arterial remodeling.
In patients with idiopathic pulmonary arterial hypertension (PAH), targeted medical therapies, including oral phosphodiesterase type 5 inhibitors (PDE5i), improve endothelial cell dysfunction, have vasodilatory and anti-proliferative effects on the pulmonary vasculature, reduce the right ventricular afterload and improve symptoms, exercise capacity, and clinical outcomes in randomized trials.
Several studies suggested a potential effect of PDE5i in COPD on dyspnea, exertional capacity and quality of life.
However, these results were based on including small number of patients with heterogenous severity of lung disease and usually without complete hemodynamic evaluation.
Data are lacking regarding the benefit/risk ratio of these treatments in the context of severe PH due to COPD.
The main objective to this randomized controlled trial (16 weeks) is to evaluate the efficacy and safety of an oral PDE5i, tadalafil, in patients with severe PH due to COPD.
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David Pr MONTANI, PU-PH
- Phone Number: +33 01 45 21 78 85
- Email: david.montani@aphp.fr
Study Locations
-
-
-
Kremlin Bicêtre, France, 94270
- Recruiting
- Kremlin Bicêtre
-
Contact:
- David Pr MONTANI
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients >18 and <80 years at inclusion,
- Dyspnea WHO functional class II to IV,
Severe precapillary pulmonary hypertension defined by :
- a mean pulmonary artery pressure (mPAP) >35 mmHg or mPAP ≥25 mmHg with a cardiac index < 2.5 L/min/m²
- associated with normal pulmonary artery wedge pressure (PawP ≤15 mmHg)
- and pulmonary vascular resistance (PVR) >3 WU
- COPD diagnosed according to current international recommendation with persistent airflow limitation defined by post-bronchodilatator Forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC): FEV1/FVC < 0.70,
- Naive patients from specific PH treatments (bosentan, ambrisentan, macitentan, sildenafil, tadalafil, riociguat, epoprostenol, treprostinil, iloprost),
- Treatments for COPD need to be stable for at least 1 month before screening visit,
- Patients who fulfill criteria for a supplemental long-term oxygen therapy need to be supplied sufficiently before study entry. The amount of supplemental oxygen and the delivery method need to be stable for at least 1 month before screening visit,
- Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period,
- Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures.
- Affiliation to a social security regime,
Exclusion Criteria:
- Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,
- Patients with underlying medical disorders and anticipated life expectancy below 12 months (eg active cancer disease with localized and/or metastasized tumor mass),
- PH not due to chronic respiratory diseases (group 1, 2, 4 or 5 of the clinical classification of PH),
- Other respiratory diseases: interstitial lung disease, sarcoidosis, lymphangioleiomyomatosis, histiocytosis, or untreated sleep apnea disorders,
- 6-minutes walk distance < 50 m or patients unable to perform the 6-minutes walk test,
- Exacerbation of the COPD requiring hospitalization in the last 8 weeks before screening,
- COPD with mild (> 80% predicted value) or severe (FEV1 <30% predicted value) airflow limitation,
- Patients listed for lung transplantation at the time of inclusion,
- Systolic left ventricular dysfunction with left ventricular ejection fraction <40% on echocardiography,
- Patient on AME (state medical aid),
- Participation in another clinical trial during the preceding 3 months and during the study,
- Pregnant women, or breast-feeding women, or women with childbearing potential not using a combination of condoms and a safe and highly effective contraception method (hormonal contraception with implants or oral contraceptives, or intrauterine devices) and one month after the end of the study, WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL],
- Patient under guardianship or curatorship
Non-inclusion criteria related to treatment by tadalafil:
Contraindication to tadalafil:
- Severe renal failure (creatinine clearance < 30 mL/min/1,73 m2)
- Severe liver cirrhosis Child-Plugh C
- Severe systemic hypotension <90/50
- Recent myocardial infarction <90 days
- Medical history of anterior ischemic optic neuropathy
- Hypersensitivity to tadalafil or any of the excipients
- Concomitant use of potent CYP3A4 inhibitors or inducers, soluble guanylate cyclase stimulator (riociguat), other PDE5 inhibitors or nitrates or doxazosin
Cardiovascular diseases:
- Clinically significant aortic and mitral valve disease
- Pericardial constriction
- Restrictive or congestive cardiomyopathy
- Significant left ventricular dysfunction
- Life-threatening arrhythmias
- Symptomatic coronary artery disease
- Uncontrolled hypertension.
- Angulation of the penis, cavernosal fibrosis, Peyronie's disease or history of priapism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
Oral Tadalafil 40 mg or Tadalafil 20 mg [(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)].
|
Oral Tadalafil
Other Names:
|
Placebo Comparator: Control arm
Oral Placebo 40 mg or Placebo 20 mg [(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)].
|
Oral Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 minute Walk
Time Frame: 16 weeks
|
The distance cover in meter during a 6-minute walk at week 16 post-randomization for patients treated with tadalafil compared to placebo
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2024
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
September 1, 2026
Study Registration Dates
First Submitted
April 25, 2023
First Submitted That Met QC Criteria
April 25, 2023
First Posted (Actual)
May 6, 2023
Study Record Updates
Last Update Posted (Actual)
April 4, 2024
Last Update Submitted That Met QC Criteria
April 3, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Disease Attributes
- Chronic Disease
- Hypertension
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Hypertension, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Tadalafil
Other Study ID Numbers
- APHP211052
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
-
Poitiers University HospitalCompletedBroncho Chronic Obstructive Pulmonary DiseaseFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States